Hospital
Ochsner Morgan City LLC
Ochsner Morgan City LLC was paid $10.29M by Medicaid between Oct 2019 and Dec 2024, across 157 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoOCHSNER MORGAN CITY LLC
MORGAN CITY, LA 70380
MORGAN CITY, LA 70380
33aNPI1205482023assigned 08/16/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.29M
24GClaims288,895
24DCodes billed157
24AFirst – last monthOct 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#34 of 96
Median peer was paid$5.17M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 10,147 | $516K | |
| 2020 | 34,122 | $1.04M | |
| 2021 | 56,644 | $1.87M | |
| 2022 | 68,151 | $2.46M | |
| 2023 | 77,147 | $2.81M | |
| 2024incomplete | 42,684 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 32,566 | 29,610 | $3.48M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 28,171 | 25,674 | $1.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 5,685 | 5,221 | $701K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6.1% | 15,336 | 14,107 | $629K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.5% | 6,982 | 6,375 | $564K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.4% | 10,764 | 9,121 | $352K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.3% | 15,522 | 12,446 | $344K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 6,293 | 5,762 | $297K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 6,721 | 5,233 | $190K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.7% | 688 | 507 | $173K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 5,724 | 5,194 | $167K |
| 80053 | Comprehensive metabolic panel | 1.4% | 19,026 | 16,703 | $140K |
145 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 20,625 | $113K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 4,711 | $112K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,793 | $94K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,997 | $92K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,516 | $74K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,307 | $59K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,196 | $56K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,500 | $51K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 139 | $50K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 279 | $47K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,536 | $40K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 715 | $37K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 265 | $37K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,233 | $35K |
| 80050 | General health panel | <1% | 761 | $31K |
| 81025 | <1% | 4,451 | $31K | |
| 80061 | Lipid panel | <1% | 2,709 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,098 | $28K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,082 | $24K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 142 | $22K |
| 81000 | <1% | 6,975 | $21K | |
| 84439 | <1% | 2,673 | $19K | |
| 84484 | <1% | 2,675 | $19K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 141 | $19K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 358 | $17K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 647 | $16K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 854 | $16K |
| 83880 | <1% | 686 | $15K | |
| 83690 | <1% | 2,775 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,150 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,977 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 148 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 602 | $10K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 25 | $10K |
| 87634 | <1% | 150 | $10K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 187 | $8K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $8K |
| 83525 | <1% | 852 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 164 | $8K |
| J3490 | Unclassified drugs | <1% | 1,350 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 208 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 267 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 248 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 254 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 280 | $7K |
| 87631 | <1% | 51 | $7K | |
| 73562 | <1% | 105 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 277 | $6K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 147 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $5K |
| 81001 | <1% | 2,316 | $5K | |
| 74018 | <1% | 102 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 46 | $5K |
| 81003 | <1% | 2,481 | $4K | |
| 83735 | <1% | 817 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 133 | $3K |
| 86376 | <1% | 271 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,292 | $3K |
| 0001A | <1% | 106 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 123 | $3K |
| 81514 | <1% | 15 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 113 | $3K |
| 59025 | Fetal non-stress test | <1% | 62 | $3K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 133 | $2K |
| 86803 | <1% | 193 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 104 | $2K |
| 90677 | <1% | 48 | $2K | |
| 20610 | <1% | 89 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 130 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 49 | $2K |
| 85730 | <1% | 570 | $2K | |
| 83550 | <1% | 226 | $2K | |
| 86592 | <1% | 476 | $2K | |
| 84481 | <1% | 149 | $2K | |
| 87581 | <1% | 51 | $2K | |
| 87486 | <1% | 51 | $2K | |
| 73630 | <1% | 26 | $1K | |
| 85610 | <1% | 581 | $1K | |
| 85027 | <1% | 344 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 34 | $1K |
| 86703 | <1% | 114 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 262 | $1K |
| 83540 | <1% | 240 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,806 | $1K |
| 83605 | <1% | 155 | $1K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 110 | $1K |
| 84436 | <1% | 200 | $1K | |
| 82962 | <1% | 461 | $1K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 27 | $1K |
| 86787 | <1% | 104 | $926.90 | |
| 0004A | <1% | 23 | $899.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 454 | $795.73 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 269 | $731.13 |
| 84480 | <1% | 89 | $695.86 | |
| 82105 | <1% | 46 | $618.40 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 382 | $585.93 |
| 0002A | <1% | 13 | $525.88 | |
| 73130 | <1% | 12 | $511.66 | |
| 90715 | <1% | 76 | $460.05 | |
| 80074 | <1% | 12 | $447.96 | |
| 87081 | <1% | 48 | $399.54 | |
| 76801 | <1% | 16 | $382.87 | |
| 82728 | <1% | 28 | $370.08 | |
| 84702 | <1% | 25 | $347.58 | |
| 90686 | <1% | 97 | $337.98 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 75 | $286.90 |
| 86850 | <1% | 55 | $232.88 | |
| 86696 | <1% | 12 | $221.84 | |
| 87077 | <1% | 32 | $211.84 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 16 | $204.55 |
| 87186 | <1% | 34 | $200.61 | |
| 82043 | <1% | 36 | $198.56 | |
| 94761 | <1% | 14 | $193.37 | |
| 82570 | <1% | 36 | $183.22 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 28 | $172.18 |
| 87088 | <1% | 28 | $170.62 | |
| 86695 | <1% | 12 | $151.24 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 44 | $126.10 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 20 | $110.92 |
| 80069 | <1% | 12 | $96.52 | |
| 86900 | <1% | 42 | $87.19 | |
| 86901 | <1% | 42 | $87.19 | |
| 81002 | <1% | 28 | $84.19 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 41 | $77.76 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 79 | $72.67 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 39 | $70.39 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 63 | $57.62 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 228 | $54.51 |
| 82950 | <1% | 13 | $52.64 | |
| 82947 | <1% | 30 | $40.51 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 14 | $40.44 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 45 | $37.43 |
| J2704 | Injection, propofol, 10 mg | <1% | 139 | $18.13 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 17 | $13.92 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $8.02 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 116 | $1.43 |
| 91300 | 0% | 234 | $0.00 | |
| 99001 | 0% | 70 | $0.00 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | 0% | 23 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 17 | $0.00 |
| A9270 | Non-covered item or service | 0% | 34 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 59 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 15 | $0.00 |
| 90656 | 0% | 28 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEBLANC, FERNIS (CEO)
Parent organizationOCHSNER MORGAN CITY LLC
| Provider | Location | Paid |
|---|---|---|
| Ochsner Bayou LLC | Raceland, LA | $29.19M |
| Ochsner Bayou, LLC | Raceland, LA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.